Medical Insights with Dr. Thomas Blom

In this episode of Medical Insights with Dr. Thomas Blom, Dr. Blom sits down with medical oncologist Dr. Richard Lee to discuss the rapidly evolving landscape of breast cancer treatment.

Together, they break down three major advances transforming modern oncology: optimizing Ovarian Function Suppression (OFS) in early-stage premenopausal patients, leveraging circulating tumor DNA (ctDNA) and Breast Cancer Index (BCI) for precision risk stratification, and navigating the rise of Antibody-Drug Conjugates (ADCs) like Enhertu across frontline settings.

Key Episode Topics

Ovarian Function Suppression (OFS): How shutting down ovarian function in premenopausal, ER-positive patients mimics chemotherapy-induced menopause to prevent recurrence in high-risk early-stage breast cancer.

De-escalation & Risk Stratification: Utilizing genomic tools like Oncotype DX and the Breast Cancer Index (BCI) to tailor extended endocrine therapy (years 5–10) and safely reduce cytotoxic chemotherapy reliance.

Endocrine Resistance & Novel Oral SERDs: Managing ESR1 mutation escape mechanisms with next-generation oral selective estrogen receptor degraders (SERDs) like elacestrant, imlunestrant, and camizestrant.

Liquid Biopsy & ctDNA Monitoring: How blood-based circulating tumor DNA testing allows clinicians to detect emerging mutations and genomic progression before radiographic changes occur.

Antibody-Drug Conjugates (ADCs): The "guided missile" approach to targeted chemotherapy delivery—exploring how drugs like Enhertu (trastuzumab deruxtecan) are shifting into HER2-low, HER2-ultralow, and pre-surgical neoadjuvant settings.

References & Mentioned Studies

SOFT & TEXT Trials: Landmark clinical trials validating the survival benefit of adding ovarian function suppression to tamoxifen or aromatase inhibitors in premenopausal women.

RXPONDER Trial: Evaluating genomic recurrence scoring and chemotherapy benefits in node-positive, HR-positive breast cancer.

SERENA-6 Trial: Investigating ctDNA-guided treatment switches to oral SERDs upon detection of emergent ESR1 mutations prior to radiographic progression.

ATLAS & MA17R Trials: Clinical data supporting extended duration endocrine therapy beyond the initial 5 years.

About The Show

Medical Insights with Dr. Thomas Blom brings you in-depth discussions with leading medical experts on the latest innovations, clinical trial data, and treatment strategies reshaping modern healthcare and patient outcomes.

Disclaimer: Medical Insights with Dr. Thomas Blom is for educational and entertainment purposes only and does not substitute for professional medical advice, diagnosis, or treatment.

In this episode of Medical Insights, Dr. Thomas Blom sits down with Dr. Andrew Evens of Rutgers Cancer Institute about major advances in Hodgkin lymphoma. They review the disease’s treatment history from early radiation to MOPP and long-standing ABVD, then focus on recent efforts to maintain high cure rates while reducing long-term toxicity. Evens describes the Holistic (Hodgkin International Study for Individualized Care) consortium, which uses clinical trial and registry data from 30 centers and 30,000+ cases to provide dynamic, individualized risk estimates and future projections of late effects. For advanced-stage disease, they discuss the shift from brentuximab-based therapy after ECHELON-1 to nivolumab-AVD after SWOG 1826, citing improved efficacy and tolerability. They cover European BreCAV use, early-stage ABVD decision factors, limited post-treatment imaging, and a planned relapse trial (TARGET-HL) testing transplant-sparing targeted therapy plus radiation.

00:00 Welcome and Overview

00:42 Hodgkin Treatment History

03:10 Holistic Risk Model

11:46 Advanced Stage Standards

17:21 Europe vs North America

22:41 Early Stage Strategy

30:36 Survivorship Monitoring

35:03 Relapse and New Trials

39:03 Closing Thoughts

• The Case Profile: A deep dive into John Hancock's lifestyle, affluent high-purine diet, significant alcohol consumption, and extreme occupational stress managing the American Revolution.
• The History of Podagra: How Hancock suffered from severe, crippling tophaceous gout that left him largely bedridden and cachectic toward the end of his life.
• The Final Hour: A chronological breakdown of October 8, 1793, from his sudden 7:00 AM onset of dyspnea (shortness of breath) and stupor to his death at 8:00 AM.
• The Modern ICU Workup: How modern Emergency Medical Services (EMS) and critical care physicians would treat and diagnose a patient presenting in this state today (from rapid intubation to CT angiograms).
• Historical Medical Trivia: The surprising connection between Benjamin Franklin, a French physician, and the introduction of the autumn crocus (Colchicum autumnale)—the precursor to modern colchicine—to the United States.

• Pulmonary Embolism (PE): Highly probable given his prolonged immobility and chronic bedbound state.
• Cardiovascular Event: Acute Myocardial Infarction (AMI) or a malignant arrhythmia stemming from chronic kidney disease.
• Sepsis / Septic Arthritis: An infection potentially infiltrating his severely damaged, tophaceous joints.
• Colchicine Toxicity: Could his primitive homeopathic remedies have built up to toxic levels due to progressive renal failure?
• Pneumonia: A common terminal event for chronically ill, bedbound patients in the 18th century.

The treatment landscape for multiple myeloma is shifting at absolute lightning speed. In this episode, we dive deep into the latest clinical breakthroughs, emerging frontline standards, and the groundbreaking immunotherapies rapidly redefining patient care.

Joining the conversation is Dr. Dan Vogl, Associate Professor of Medicine and Myeloma Specialist at Penn Medicine's Abramson Cancer Center. Together, we break down the complex balancing act between treatment efficacy, long-term toxicity, and modern sequencing strategy. We examine everything from the transition toward quadruplet induction therapy to the revolutionary potential of off-the-shelf T-cell engagers and personalized cellular therapies.

KEY TAKEAWAYS FROM THIS EPISODE:

The Evolution of Frontline Therapy: Moving from triplet regimens to quadruplet combinations, and how the addition of monoclonal antibodies like daratumumab is shaping expectations for newly diagnosed patients.

The Overall Survival Confounding Dilemma: Why evaluating long-term survival metrics in clinical trials has become increasingly difficult, and why clinical endpoints like progression-free survival (PFS) remain a point of healthy debate among oncologists.

Redefining Transplant Eligibility: Shifting the conversation away from binary age limits and toward a more comprehensive, nuanced assessment of patient frailty and functional resilience.

The Rise of Bispecific Antibodies (TCEs): A clear look at how dual-targeting therapies work to engage the immune system, their expanding role in early relapse, and insights into Penn's ongoing trials testing fixed-duration vs. indefinite dosing.

CAR T-Cell Therapy in Practice: Demystifying the logistical timeline, cellular manufacturing process, and profound clinical response rates of chimeric antigen receptor T-cell therapies, alongside a candid look at rare, long-term toxicities.

The Future of Community-Based Oncology: How specialized care delivery models are scaling to bring advanced, high-stakes immunotherapies safely to regional hospitals and community cancer centers.

If you find this deep dive into modern hematologic oncology helpful, please hit that subscribe button, leave a comment with your thoughts, and share the episode with colleagues or families navigating a multiple myeloma journey.

Disclaimer: The information provided in this podcast is for educational and informational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment plan.

#MultipleMyeloma #OncologyPodcast #CancerResearch

This episode of Medical Insights with Dr. Thomas Blom features Dr. John Heim, a thoracic surgeon from Penn Medicine Princeton. The discussion focuses on the common clinical scenario of discovering pulmonary nodules through imaging and the strategic approach to managing early-stage lung cancer.

Episode Overview

In an era of increased CT imaging, "incidental" pulmonary nodules are being found more frequently than ever. Dr. Blom and Dr. Heim break down the anxiety surrounding these findings, the actual statistical risks of cancer, and the protocols used to ensure patient safety while avoiding unnecessary surgery.

Key Discussion Points

Defining the Nodule: Why a "growth" or "tumor" doesn't always mean cancer.

The 15% Rule: Statistically, 15 out of 100 people over age 50 have lung nodules, but only a small fraction are malignant.

Fleischner Society Guidelines: The history and importance of these protocols in determining when to watch a nodule and when to intervene.

Risk Factors Beyond Smoking: The roles of radon and asbestos exposure in lung cancer development.

Advanced Imaging (PET Scans): How sugar metabolism helps identify hypermetabolic activity in potential tumors.

The Biopsy Process: Understanding bronchoscopy, EBUS (Endoscopic Bronchial Ultrasound), and CT-guided biopsies.

Surgical Philosophy: Why staging and pathology are the most critical steps before entering the operating room.

Subscribe for more medical insights and deep dives into modern healthcare management.

#LungCancer #Oncology

In this episode of Medical Insights, Dr. Thomas Blom sits down with Dr. Josh Pepek , a leading radiation oncologist in Central New Jersey with Aster Care. Together, they break down the complex decision-making process for men diagnosed with early-stage prostate cancer.

From understanding the Gleason score and risk stratification to the nuances of active surveillance, this deep dive explores how modern medicine is moving toward highly individualized care. Whether you are a patient, a family member, or a medical professional, this episode provides a clear map of the current landscape of prostate cancer treatment.

Key Topics Covered:

* Risk Stratification: Understanding Low, Intermediate, and High-risk categories using NCCN guidelines.

* Active Surveillance: Who can safely watch and wait to avoid treatment side effects?

* Radiation vs. Surgery: A candid look at how comorbidities, age, and urinary symptoms influence the choice between a prostatectomy and radiation.

* Side Effect Management: How new technologies like perirectal spacers (Hydrogel) are significantly reducing rectal toxicity.

* Treatment Modalities: A breakdown of IMRT (Intensity Modulated Radiation Therapy), Brachytherapy (seeds), and the role of Hormone Therapy (ADT).

About the Guest:

Dr. Joseph Pepek is a radiation oncologist based in Central New Jersey. He specializes in utilizing advanced radiation techniques to treat localized cancers while prioritizing the patient’s quality of life and long-term outcomes.

About the Podcast:

Medical Insights with Dr. Thomas Blom provides in-depth conversations with specialists to bridge the gap between complex medical data and patient-centered care.

#ProstateCancer #RadiationOncology #MensHealth

In this episode of Medical Insights, Dr. Thomas Blom sits down with Dr. Sheetal Shrimanker, a hematologist-oncologist at Penn Medicine, to demystify the complex world of plasma cell disorders.

Receiving a lab result showing an "abnormal protein" can be a frightening experience. Dr. Shrimanker explains exactly what a monoclonal protein is, how physicians risk-stratify patients, and the crucial differences between a benign condition like MGUS and active Multiple Myeloma.

In This Episode:

* The First Red Flag: What is a monoclonal protein and why is it often found by accident?

* MGUS vs. Smoldering Myeloma: Understanding the 1% annual risk of progression and when a bone marrow biopsy is necessary.

* The CRAB Criteria: How specialists look for end-organ damage (Calcium, Renal, Anemia, Bone).

* Modern Staging: Why traditional cancer stages don't apply to blood cancers and how cytogenetics (DNA testing) dictates the plan.

* Treatment Pathways: A look at induction therapy, stem cell transplants, and the role of medications like Daratumumab.

* The Future of Care: An introduction to Bi-specific Antibodies and CAR T-cell therapy.

About Our Guest:

Dr. Sheetal Shrimanker is a board-certified hematologist-oncologist practicing with Penn Medicine in Princeton, New Jersey. She specializes in treating blood-based malignancies and guiding patients through complex immunotherapy and transplant journeys.

0:00 Introduction to Monoclonal Proteins

2:24 Workup for Monoclonal Proteins (MGUS)

4:43 Criteria for Bone Marrow Biopsy & Imaging

6:23 Causes of MGUS (Viruses & Autoimmune)

7:42 Prognosis and Risk Counseling

9:39 Distinguishing MGUS, Smoldering Myeloma, and Multiple Myeloma

11:42 Staging and Cytogenetics

14:48 Treatment Pathways & Induction Therapy

18:34 Stem Cell Transplants

19:56 Managing Risks (Infection, Blood Clots)

22:36 Future Care: CAR T-Cell Therapy

24:28 Bi-specific Antibodies

26:53 Treating Smoldering Myeloma

28:34 Genetic Predisposition

29:52 Monoclonal Gammopathy of Renal/Neurological Significance

31:52 Related Disorders (Waldenström’s & Amyloidosis)

34:19 Long-term Management, Maintenance, and IVIG

#cancerresearch

Join host Dr. Thomas Blom and guest Dr. Rohit Bhalla as they provide a comprehensive overview of infection risks for chemotherapy patients and practical strategies to prevent them, including vaccination, masking, and lifestyle modifications. Dr. Rohit Bhalla, an infectious disease specialist, shares expert insights on immune system management, travel precautions, and specific risks for patients with conditions like asplenia and undergoing bone marrow transplants.

This episode equips patients and clinicians with actionable insights to minimize infection risks during chemotherapy and beyond, emphasizing proactive vaccination, hygiene, and environmental precautions.

Main Topics:

• How chemotherapy impacts immune function and infection risk timeline
• Essential vaccinations before and during chemotherapy
• Best practices for infection prevention: masking, hygiene, and pet care
• Risks associated with neutropenic periods and dietary precautions
• Prophylactic medications and growth factor support to reduce infection risk
• Special considerations for patients with spleen removal or bone marrow transplants
• Emerging infectious threats like Babesia and their geographic patterns

In this episode of Medical Insights with Dr. Thomas Blom, host Dr. Blom welcomes Dr. Joseph Ho, a Hematologist-Oncologist from the Princeton Medical Group. Together, they demystify Chronic Lymphocytic Leukemia (CLL), a diagnosis that often sounds urgent and frightening but frequently follows a very different path than other cancers.

From the initial shock of the word "leukemia" to modern, chemotherapy-free treatment options, this conversation provides a comprehensive overview for patients and families navigating a CLL diagnosis.

Key Topics Covered:

•Leukemia vs. Lymphoma: Understanding why CLL is considered a chronic, low-grade, and often non-aggressive disease rather than an immediate medical emergency.

•The "Watch and Wait" Paradigm: Why two-thirds to three-fourths of patients start with surveillance rather than active treatment. Dr. Ho explains why "stirring the pot" too early isn't always best for the patient.

•Triggers for Treatment: What doctors look for—such as drenching night sweats, fatigue, rapid white blood cell doubling time, or specific genetic markers like the p53 mutation—before starting therapy.

•Modern Treatment Options: How the field has moved away from traditional chemotherapy toward targeted oral therapies like Acalabrutinib and Venetoclax

•Living with CLL: Practical advice on vaccinations (including the importance of the Shingrix vaccine), infection risks, and maintaining a normal lifestyle without "living in a bubble".

•Long-term Risks & Family Planning: Discussing the slightly increased risk for skin cancers and the familial (but not directly inherited) nature of the disease.

About the Guest:

Dr. Joseph Ho is a Hematologist-Oncologist at the Princeton Medical Group in Princeton, New Jersey. He specializes in the treatment of blood cancers and provides expert insights into the evolving landscape of CLL management.

Navigating end-of-life care decisions is one of the most emotionally complex challenges patients and their families face during a cancer journey. Dr. Michael Levitt, a medical oncologist with Hackensack Meridian Health and director of hospice services for Swan Hospice in New Jersey, clarifies the often-misunderstood realities of palliative and hospice care to help families make informed, compassionate choices.

Key Takeaways

Understand the critical distinction between palliative care, which can be utilized alongside active cancer treatments, and hospice care, which focuses entirely on comfort and symptom management.

Discover the comprehensive, team-based benefits of hospice, which include covered medical equipment, social workers, clergy, and home health aides to support both the patient and the family.

Learn the importance of establishing a POLST (Practitioner Orders for Life-Sustaining Treatment) form to clearly define advanced directives regarding life support and artificial feeding.

Master the realities of the New Jersey Medical Marijuana Program as a legal, effective adjunct for managing chronic pain, nausea, and treatment toxicities when traditional prescriptions fall short.